Get access

Different mechanisms can lead to the same altered HLA class I phenotype in tumors

Authors

  • T. Rodriguez,

    1. Servicio de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Granada, Spain
    Search for more papers by this author
  • N. Aptsiauri,

    1. Servicio de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Granada, Spain
    Search for more papers by this author
  • R. Méndez,

    1. Servicio de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Granada, Spain
    Search for more papers by this author
  • P. Jimenez,

    1. Servicio de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Granada, Spain
    Search for more papers by this author
  • F. Ruiz-Cabello,

    1. Servicio de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Granada, Spain
    2. Departamento de Bioquimica, Biologia Molecular 3 e Inmunología, Facultad de Medicina, Universidad de Granada, Granada, Spain
    Search for more papers by this author
  • F Garrido

    Corresponding author
    1. Servicio de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Granada, Spain
    2. Departamento de Bioquimica, Biologia Molecular 3 e Inmunología, Facultad de Medicina, Universidad de Granada, Granada, Spain
      Federico Garrido
      Hospital Universitario Virgen de las Nieves
      Dept. de Análisis Clínicos
      Avd. Fuerzas Armadas 2
      18014 Granada
      Spain
      Tel: 34 958 020319
      Fax: 34 958 283147
      e-mail: federico.garrido.sspa@juntadeandalucia.es
    Search for more papers by this author

Federico Garrido
Hospital Universitario Virgen de las Nieves
Dept. de Análisis Clínicos
Avd. Fuerzas Armadas 2
18014 Granada
Spain
Tel: 34 958 020319
Fax: 34 958 283147
e-mail: federico.garrido.sspa@juntadeandalucia.es

Abstract

Human leukocyte antigen (HLA) class I plays an important role in tumor recognition and rejection. Total or selective losses of HLA class I antigens (classified into seven HLA class I altered phenotypes) represent one of the main routes of tumor escape from immune surveillance. Abnormal expression of HLA class I has been reported in different human tumor samples with distinct underlying mechanisms. Notably, different molecular mechanisms can generate the same altered HLA class I phenotype. Here, we describe various molecular mechanisms that can lead to HLA total loss or downregulation (phenotype I) in melanoma, colorectal carcinoma and bladder cancer.

Get access to the full text of this article

Ancillary